US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GRAIL, Inc.

140.12

+3.552.60%

Post-market: 139.86-0.2600-0.19%19:56 EDT

Volume:1.92M

Turnover:277.63M

Market Cap:6.26B

PE:-14.37

High:151.46

Open:138.27

Low:136.00

Close:136.57

52wk High:151.46

52wk Low:41.50

Shares:44.67M

Float Shares:40.70M

Volume Ratio:0.96

T/O Rate:4.73%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.7487

EPS(LYR):-11.1105

ROE:-16.12%

ROA:-12.03%

PB:2.46

PE(LYR):-12.61

Loading ...

Overview Company News Filings

Grail CEO Joshua J. Ofman Disposes of Common Shares Worth $5.54 Million

FDA Advisers are Reviewing a Multicancer-Detection Test. Medicare Coverage Could Follow.

Grail Trading Halted Ahead of FDA AdCom Meeting on Galleri Blood Test

NASDAQ Trade Halt Halt News Pending at 06:55 Am

With Approval Looking Likely, How Fast Will Sales of Cancer-Screening Blood Tests Rise?

Grail Gains From More Focused FDA Review Before Galleri Advisory Panel, UBS Says

MT Newswires Live

Canaccord Genuity Remains a Buy on GRAIL Inc (GRAL)

Under the Radar: Grail Shares Surge on FDA Results

Grail Shares Jump 34.6% as US FDA Flags no Major Concerns for Co's Cancer Test

THOMSON REUTERS

Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review from FDA

Grail rallies after FDA releases briefing documents for Galleri test review

Grail rises 23.2%

GRAIL Risk-Reward Attractive Ahead of FDA Advisory Committee, UBS Says

MT Newswires Live

Grail's Galleri Test Has Large Market Potential Amid Adoption Curve Concerns, RBC Capital Markets Says

MT Newswires Live

RBC Initiates GRAIL at Sector Perform With $84 Price Target

MT Newswires Live

Grail initiated with a Sector Perform at RBC Capital

UBS Initiates a Buy Rating on GRAIL Inc (GRAL)

Grail Initiated at Buy by UBS

UBS Initiates Coverage on GRAIL With Buy Rating, $105 Price Target

MT Newswires Live

Grail Grants 55,867 Inducement RSUs to 59 New Hires Under NASDAQ Rule 5635(c)(4)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/GRAL/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GRAL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRAL\",,,,,undefined,":{"symbol":"GRAL","market":"US","secType":"STK","nameCN":"GRAIL, Inc.","latestPrice":140.12,"timestamp":1790798400000,"preClose":136.57,"halted":0,"volume":1923794,"hourTrading":{"tag":"盘后","latestPrice":139.86,"preClose":140.12,"latestTime":"19:56 EDT","volume":32521,"amount":4558526.3976,"timestamp":1790812614555,"change":-0.26,"changeRate":-0.001856,"amplitude":0.00865},"delay":0,"changeRate":0.025993995753093736,"floatShares":40696402,"shares":44666200,"eps":-9.748709,"marketStatus":"Not Yet Opened","change":3.55,"latestTime":"09-30 16:00:00 EDT","open":138.27,"high":151.4574,"low":136,"amount":277625751.73451996,"amplitude":0.113183,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.748709,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":136.57,"preHourTrading":{"tag":"盘前","latestPrice":138.27,"preClose":136.57,"latestTime":"09:29 EDT","volume":1003,"amount":136083.05809,"timestamp":1790774941030,"change":1.7,"changeRate":0.012448,"amplitude":0.045911},"postHourTrading":{"tag":"盘后","latestPrice":139.86,"preClose":140.12,"latestTime":"19:56 EDT","volume":32521,"amount":4558526.3976,"timestamp":1790812614555,"change":-0.26,"changeRate":-0.001856,"amplitude":0.00865},"volumeRatio":0.958668,"impliedVol":0.8926,"impliedVolPercentile":0.3506},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRAL\",,,,,undefined,":{"symbol":"GRAL","floatShares":40696402,"roa":"-12.03%","roe":"-16.12%","lyrEps":-11.110457,"volumeRatio":0.958668,"shares":44666200,"dividePrice":0,"high":151.4574,"amplitude":0.113183,"preClose":136.57,"low":136,"week52Low":41.5,"pbRate":"2.46","psRate":"37.87","week52High":151.4574,"institutionHeld":0,"latestPrice":140.12,"eps":-9.748709,"divideRate":0,"volume":1923794,"delay":0,"ttmEps":-9.748709,"open":138.27,"prevYearClose":85.59,"prevWeekClose":126.89,"prevMonthClose":79.37,"prevQuarterClose":68.27,"fiveDayClose":108.52,"twentyDayClose":79.79,"sixtyDayClose":68.79},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GRAL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-05","symbol":"GRAL","fiscalQuarterEnding":"2026/06","expectedEps":-2.91,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"post","actualEps":-2.56},{"market":"US","date":"2026-05-05","symbol":"GRAL","fiscalQuarterEnding":"2026/03","expectedEps":3,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1777953600000,"reportTimeType":"post","actualEps":-2.29},{"market":"US","date":"2026-02-19","symbol":"GRAL","fiscalQuarterEnding":"2025/12","expectedEps":-3.33,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":-1.86},{"market":"US","date":"2025-11-12","symbol":"GRAL","fiscalQuarterEnding":"2025/09","expectedEps":-3.4,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-2.46},{"market":"US","date":"2025-08-12","symbol":"GRAL","fiscalQuarterEnding":"2025/06","expectedEps":-3.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-3.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GRAL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GRAL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1818,"buy":0.2727,"hold":0.5455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2727,"analysts":11,"updateTime":1789704000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GRAL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GRAL","date":"2026-09-29","current":-14.373185,"percent":0,"low":-15.128394,"twenty":-7.781601,"median":-2.669291,"eighty":-0.303535,"high":-0.135365,"avg":-3.810123,"sd":3.691823,"marketCap":5924082615},"quantilePoints":[{"date":"2024-06-12","current":-0.243184,"twenty":-0.243184,"median":-0.243184,"eighty":-0.243184,"marketCap":362571424},{"date":"2024-06-28","current":-0.269888,"twenty":-0.264547,"median":-0.256536,"eighty":-0.248525,"marketCap":402385270},{"date":"2024-07-05","current":-0.275763,"twenty":-0.275763,"median":-0.271757,"eighty":-0.266328,"marketCap":411144316},{"date":"2024-07-12","current":-0.259385,"twenty":-0.273627,"median":-0.266328,"eighty":-0.249504,"marketCap":386725157},{"date":"2024-07-15","current":-0.263657,"twenty":-0.273022,"median":-0.264992,"eighty":-0.25148,"marketCap":393095372},{"date":"2024-08-02","current":-0.296236,"twenty":-0.274909,"median":-0.266328,"eighty":-0.253456,"marketCap":441668264},{"date":"2024-08-09","current":-0.310656,"twenty":-0.300615,"median":-0.272114,"eighty":-0.260667,"marketCap":463167741},{"date":"2024-08-16","current":-0.170902,"twenty":-0.29588,"median":-0.2706,"eighty":-0.248276,"marketCap":492749978},{"date":"2024-08-23","current":-0.178117,"twenty":-0.292284,"median":-0.264992,"eighty":-0.180551,"marketCap":513552907},{"date":"2024-08-30","current":-0.159595,"twenty":-0.28292,"median":-0.259385,"eighty":-0.170708,"marketCap":460148373},{"date":"2024-09-06","current":-0.145057,"twenty":-0.275763,"median":-0.247457,"eighty":-0.162201,"marketCap":418232023},{"date":"2024-09-13","current":-0.145918,"twenty":-0.275336,"median":-0.18151,"eighty":-0.152854,"marketCap":420715955},{"date":"2024-09-20","current":-0.149365,"twenty":-0.273627,"median":-0.178117,"eighty":-0.150075,"marketCap":430651682},{"date":"2024-09-27","current":-0.146457,"twenty":-0.273022,"median":-0.170741,"eighty":-0.146026,"marketCap":422268412},{"date":"2024-10-04","current":-0.135365,"twenty":-0.270458,"median":-0.165733,"eighty":-0.14454,"marketCap":390287790},{"date":"2024-10-11","current":-0.140319,"twenty":-0.269176,"median":-0.160133,"eighty":-0.142925,"marketCap":404570398},{"date":"2024-10-18","current":-0.152918,"twenty":-0.265794,"median":-0.156041,"eighty":-0.143463,"marketCap":440897901},{"date":"2024-10-25","current":-0.13978,"twenty":-0.263443,"median":-0.155556,"eighty":-0.143463,"marketCap":403017941},{"date":"2024-10-31","current":-0.146672,"twenty":-0.262589,"median":-0.153942,"eighty":-0.142688,"marketCap":422889395},{"date":"2024-11-08","current":-0.160456,"twenty":-0.259385,"median":-0.152918,"eighty":-0.142796,"marketCap":462632305},{"date":"2024-11-15","current":-0.250879,"twenty":-0.250879,"median":-0.154641,"eighty":-0.143442,"marketCap":531228205},{"date":"2024-11-22","current":-0.259924,"twenty":-0.250879,"median":-0.156041,"eighty":-0.143549,"marketCap":550380645},{"date":"2024-11-29","current":-0.277697,"twenty":-0.262044,"median":-0.156472,"eighty":-0.143635,"marketCap":588013510},{"date":"2024-12-06","current":-0.355611,"twenty":-0.27003,"median":-0.160025,"eighty":-0.14426,"marketCap":752993300},{"date":"2024-12-13","current":-0.329745,"twenty":-0.275763,"median":-0.161318,"eighty":-0.144928,"marketCap":698224042},{"date":"2024-12-20","current":-0.271984,"twenty":-0.27776,"median":-0.165841,"eighty":-0.145746,"marketCap":575917232},{"date":"2024-12-27","current":-0.308005,"twenty":-0.287312,"median":-0.170741,"eighty":-0.145918,"marketCap":652190984},{"date":"2025-01-03","current":-0.284362,"twenty":-0.289787,"median":-0.175532,"eighty":-0.146134,"marketCap":602125834},{"date":"2025-01-10","current":-0.280236,"twenty":-0.294514,"median":-0.180594,"eighty":-0.1465,"marketCap":593389633},{"date":"2025-01-17","current":-0.276189,"twenty":-0.293978,"median":-0.222157,"eighty":-0.146801,"marketCap":584821436},{"date":"2025-01-24","current":-0.412102,"twenty":-0.295346,"median":-0.234852,"eighty":-0.147318,"marketCap":872612048},{"date":"2025-01-31","current":-0.500013,"twenty":-0.298484,"median":-0.241319,"eighty":-0.14818,"marketCap":1058760325},{"date":"2025-02-07","current":-0.523498,"twenty":-0.307212,"median":-0.249504,"eighty":-0.148826,"marketCap":1108489468},{"date":"2025-02-14","current":-0.83436,"twenty":-0.31102,"median":-0.255132,"eighty":-0.149365,"marketCap":1766728591},{"date":"2025-02-21","current":-0.791697,"twenty":-0.321747,"median":-0.260916,"eighty":-0.149365,"marketCap":1604772870},{"date":"2025-02-28","current":-0.656882,"twenty":-0.34371,"median":-0.263657,"eighty":-0.149709,"marketCap":1331502572},{"date":"2025-03-07","current":-0.559345,"twenty":-0.359577,"median":-0.270244,"eighty":-0.149795,"marketCap":1133795978},{"date":"2025-03-14","current":-0.450152,"twenty":-0.414561,"median":-0.273627,"eighty":-0.15014,"marketCap":912460022},{"date":"2025-03-21","current":-0.465034,"twenty":-0.450921,"median":-0.275763,"eighty":-0.150484,"marketCap":942626791},{"date":"2025-03-28","current":-0.47791,"twenty":-0.468947,"median":-0.276427,"eighty":-0.150807,"marketCap":968726130},{"date":"2025-04-04","current":-0.416039,"twenty":-0.465703,"median":-0.277856,"eighty":-0.15113,"marketCap":843313720},{"date":"2025-04-11","current":-0.380338,"twenty":-0.459122,"median":-0.280236,"eighty":-0.151281,"marketCap":770947370},{"date":"2025-04-17","current":-0.443129,"twenty":-0.455455,"median":-0.281347,"eighty":-0.151562,"marketCap":898224019},{"date":"2025-04-25","current":-0.630246,"twenty":-0.466372,"median":-0.283965,"eighty":-0.151863,"marketCap":1277511821},{"date":"2025-05-02","current":-0.565758,"twenty":-0.478944,"median":-0.287218,"eighty":-0.15253,"marketCap":1146794916},{"date":"2025-05-09","current":-0.62862,"twenty":-0.498389,"median":-0.292296,"eighty":-0.15337,"marketCap":1274216573},{"date":"2025-05-16","current":-0.732698,"twenty":-0.51302,"median":-0.295346,"eighty":-0.153995,"marketCap":1402606531},{"date":"2025-05-23","current":-0.728564,"twenty":-0.527433,"median":-0.296725,"eighty":-0.154728,"marketCap":1394692362},{"date":"2025-05-30","current":-0.772349,"twenty":-0.542338,"median":-0.298484,"eighty":-0.155417,"marketCap":1478510603},{"date":"2025-06-06","current":-0.742094,"twenty":-0.562722,"median":-0.305137,"eighty":-0.155977,"marketCap":1420593278},{"date":"2025-06-13","current":-0.787758,"twenty":-0.602918,"median":-0.308322,"eighty":-0.156041,"marketCap":1508008868},{"date":"2025-06-20","current":-0.910282,"twenty":-0.617043,"median":-0.310838,"eighty":-0.156127,"marketCap":1742556049},{"date":"2025-06-27","current":-0.927946,"twenty":-0.628237,"median":-0.313683,"eighty":-0.156967,"marketCap":1776371133},{"date":"2025-07-03","current":-0.87796,"twenty":-0.640897,"median":-0.324667,"eighty":-0.158949,"marketCap":1680681639},{"date":"2025-07-11","current":-0.815382,"twenty":-0.656882,"median":-0.33641,"eighty":-0.159595,"marketCap":1560889904},{"date":"2025-07-18","current":-0.675007,"twenty":-0.694504,"median":-0.351643,"eighty":-0.160456,"marketCap":1292167904},{"date":"2025-07-25","current":-0.746416,"twenty":-0.703946,"median":-0.35847,"eighty":-0.160672,"marketCap":1428867181},{"date":"2025-08-01","current":-0.642872,"twenty":-0.704698,"median":-0.372061,"eighty":-0.161318,"marketCap":1230653229},{"date":"2025-08-08","current":-0.619382,"twenty":-0.703946,"median":-0.384644,"eighty":-0.164764,"marketCap":1185686362},{"date":"2025-08-15","current":-2.618835,"twenty":-0.718416,"median":-0.412102,"eighty":-0.165733,"marketCap":1160018171},{"date":"2025-08-22","current":-2.697774,"twenty":-0.721799,"median":-0.415789,"eighty":-0.165949,"marketCap":1194984536},{"date":"2025-08-29","current":-2.7759,"twenty":-0.732698,"median":-0.419718,"eighty":-0.170579,"marketCap":1229590423},{"date":"2025-09-05","current":-2.733582,"twenty":-0.742958,"median":-0.427076,"eighty":-0.170837,"marketCap":1210845568},{"date":"2025-09-12","current":-3.145369,"twenty":-0.751941,"median":-0.435395,"eighty":-0.172539,"marketCap":1393247431},{"date":"2025-09-19","current":-3.221867,"twenty":-0.757193,"median":-0.443129,"eighty":-0.177083,"marketCap":1427132362},{"date":"2025-09-26","current":-3.927439,"twenty":-0.772199,"median":-0.450236,"eighty":-0.179927,"marketCap":1739666779},{"date":"2025-10-03","current":-5.267781,"twenty":-0.790326,"median":-0.453995,"eighty":-0.180724,"marketCap":2333374029},{"date":"2025-10-10","current":-5.788618,"twenty":-0.792794,"median":-0.466707,"eighty":-0.18193,"marketCap":2564079942},{"date":"2025-10-17","current":-7.032117,"twenty":-0.810572,"median":-0.474733,"eighty":-0.214168,"marketCap":3114890311},{"date":"2025-10-24","current":-6.726125,"twenty":-0.834423,"median":-0.483801,"eighty":-0.232186,"marketCap":2979350587},{"date":"2025-10-31","current":-7.417862,"twenty":-0.86879,"median":-0.497307,"eighty":-0.23482,"marketCap":3285756878},{"date":"2025-11-07","current":-6.515349,"twenty":-0.90953,"median":-0.508594,"eighty":-0.23627,"marketCap":2885986787},{"date":"2025-11-14","current":-7.32206,"twenty":-1.284423,"median":-0.515869,"eighty":-0.238888,"marketCap":3243320953},{"date":"2025-11-21","current":-8.218834,"twenty":-2.622741,"median":-0.524768,"eighty":-0.242438,"marketCap":3338827399},{"date":"2025-11-28","current":-10.592844,"twenty":-2.668803,"median":-0.533066,"eighty":-0.245748,"marketCap":4303247596},{"date":"2025-12-05","current":-10.047321,"twenty":-2.733908,"median":-0.545714,"eighty":-0.248685,"marketCap":4081633659},{"date":"2025-12-12","current":-9.121802,"twenty":-2.773947,"median":-0.559678,"eighty":-0.249586,"marketCap":3705650118},{"date":"2025-12-19","current":-8.474563,"twenty":-3.023948,"median":-0.565758,"eighty":-0.250383,"marketCap":3442715024},{"date":"2025-12-26","current":-8.814736,"twenty":-3.115583,"median":-0.600672,"eighty":-0.254281,"marketCap":3580907004},{"date":"2026-01-02","current":-8.213077,"twenty":-3.191837,"median":-0.607471,"eighty":-0.259493,"marketCap":3336488466},{"date":"2026-01-09","current":-9.407758,"twenty":-3.756539,"median":-0.615248,"eighty":-0.260321,"marketCap":3821817142},{"date":"2026-01-16","current":-9.350183,"twenty":-4.63773,"median":-0.618067,"eighty":-0.262044,"marketCap":3798427809},{"date":"2026-01-23","current":-11.136928,"twenty":-5.050494,"median":-0.621638,"eighty":-0.262589,"marketCap":4524276801},{"date":"2026-01-30","current":-9.689876,"twenty":-5.381714,"median":-0.623725,"eighty":-0.263657,"marketCap":3936424878},{"date":"2026-02-06","current":-9.025844,"twenty":-5.92371,"median":-0.62862,"eighty":-0.266328,"marketCap":3666667895},{"date":"2026-02-13","current":-9.201448,"twenty":-6.490935,"median":-0.634416,"eighty":-0.269888,"marketCap":3738005363},{"date":"2026-02-20","current":-10.027753,"twenty":-6.738169,"median":-0.640672,"eighty":-0.270458,"marketCap":4094842980},{"date":"2026-02-27","current":-5.738328,"twenty":-6.59852,"median":-0.642551,"eighty":-0.271707,"marketCap":2343252016},{"date":"2026-03-06","current":-5.1161,"twenty":-6.525603,"median":-0.645131,"eighty":-0.273298,"marketCap":2089164448},{"date":"2026-03-13","current":-4.454105,"twenty":-6.495818,"median":-0.656882,"eighty":-0.273627,"marketCap":1818838106},{"date":"2026-03-20","current":-4.868977,"twenty":-6.467497,"median":-0.678025,"eighty":-0.275336,"marketCap":1988251759},{"date":"2026-03-27","current":-5.23965,"twenty":-6.370491,"median":-0.694504,"eighty":-0.275763,"marketCap":2139616500},{"date":"2026-04-02","current":-5.384303,"twenty":-6.22661,"median":-0.703946,"eighty":-0.276019,"marketCap":2198685668},{"date":"2026-04-10","current":-4.777565,"twenty":-6.012578,"median":-0.718792,"eighty":-0.276332,"marketCap":1950923327},{"date":"2026-04-17","current":-4.969431,"twenty":-5.842655,"median":-0.720859,"eighty":-0.277189,"marketCap":2029272014},{"date":"2026-04-24","current":-5.087966,"twenty":-5.758444,"median":-0.724241,"eighty":-0.277697,"marketCap":2077675915},{"date":"2026-05-01","current":-5.472702,"twenty":-5.73481,"median":-0.732698,"eighty":-0.277887,"marketCap":2234783492},{"date":"2026-05-08","current":-6.830613,"twenty":-5.758444,"median":-0.740497,"eighty":-0.278585,"marketCap":2700312031},{"date":"2026-05-15","current":-6.709025,"twenty":-6.393277,"median":-0.747877,"eighty":-0.279728,"marketCap":2652245447},{"date":"2026-05-22","current":-7.366901,"twenty":-6.535065,"median":-0.752054,"eighty":-0.280426,"marketCap":2912320000},{"date":"2026-05-29","current":-8.024776,"twenty":-6.608933,"median":-0.75506,"eighty":-0.280871,"marketCap":3172394554},{"date":"2026-06-05","current":-7.224687,"twenty":-6.675155,"median":-0.757458,"eighty":-0.282109,"marketCap":2856099264},{"date":"2026-06-12","current":-6.530986,"twenty":-6.667338,"median":-0.770188,"eighty":-0.283378,"marketCap":2581862234},{"date":"2026-06-18","current":-6.453909,"twenty":-6.64758,"median":-0.774322,"eighty":-0.283727,"marketCap":2551391453},{"date":"2026-06-26","current":-7.226858,"twenty":-6.705551,"median":-0.790201,"eighty":-0.284901,"marketCap":2856957596},{"date":"2026-07-02","current":-7.394041,"twenty":-6.741593,"median":-0.791697,"eighty":-0.287059,"marketCap":2923049149},{"date":"2026-07-10","current":-8.227784,"twenty":-6.830613,"median":-0.793866,"eighty":-0.287218,"marketCap":3252648583},{"date":"2026-07-17","current":-7.811998,"twenty":-6.920316,"median":-0.805047,"eighty":-0.287691,"marketCap":3088278032},{"date":"2026-07-24","current":-7.638301,"twenty":-7.010823,"median":-0.819893,"eighty":-0.291185,"marketCap":3019611483},{"date":"2026-07-31","current":-7.722978,"twenty":-7.028862,"median":-0.830133,"eighty":-0.292962,"marketCap":3053086426},{"date":"2026-08-07","current":-7.231699,"twenty":-7.225121,"median":-0.842819,"eighty":-0.294422,"marketCap":2831839235},{"date":"2026-08-14","current":-7.783772,"twenty":-7.278539,"median":-0.870399,"eighty":-0.295212,"marketCap":3048023808},{"date":"2026-08-21","current":-8.893621,"twenty":-7.372329,"median":-0.87796,"eighty":-0.295699,"marketCap":3482626264},{"date":"2026-08-28","current":-9.410334,"twenty":-7.428129,"median":-0.917705,"eighty":-0.296146,"marketCap":3684964305},{"date":"2026-09-04","current":-9.195892,"twenty":-7.480979,"median":-0.966282,"eighty":-0.297019,"marketCap":3600991785},{"date":"2026-09-11","current":-8.846854,"twenty":-7.492831,"median":-2.572448,"eighty":-0.297976,"marketCap":3464313109},{"date":"2026-09-18","current":-9.119469,"twenty":-7.639447,"median":-2.628601,"eighty":-0.298484,"marketCap":3571065408},{"date":"2026-09-25","current":-14.282035,"twenty":-7.746291,"median":-2.668477,"eighty":-0.301515,"marketCap":5592659159},{"date":"2026-09-29","current":-15.128394,"twenty":-7.781601,"median":-2.669291,"eighty":-0.303535,"marketCap":5924082615}],"updateTime":1790807177975},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GRAL\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669223436","title":"Grail CEO Joshua J. Ofman Disposes of Common Shares Worth $5.54 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669223436","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669223436?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:37","pubTimestamp":1790195863,"startTime":"0","endTime":"0","summary":"Grail CEO Joshua J. Ofman disposes of common shares worth $5.54 millionGrail CEO Joshua J. Ofman sold 61,452 common shares on Sep. 21, 2026, cutting his stake to 362,271 shares.Sales priced between US","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL4n4Sgc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Grail CEO Joshua J. Ofman Disposes of Common Shares Worth $5.54 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669485793","title":"FDA Advisers are Reviewing a Multicancer-Detection Test. Medicare Coverage Could Follow.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669485793","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669485793?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:39","pubTimestamp":1790167140,"startTime":"0","endTime":"0","summary":"Grail's Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancersGrail sells the Galleri test, which screens for 50 types of cancer usi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669835544","title":"Grail Trading Halted Ahead of FDA AdCom Meeting on Galleri Blood Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2669835544","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669835544?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:52","pubTimestamp":1790164320,"startTime":"0","endTime":"0","summary":"Trading in shares of Grail is halted on Wednesday ahead of a Food and Drug Administration advisory committee meeting to discuss the diagnostic company's proposed multi-cancer blood test.Grail is seeking FDA approval of Galleri, a blood test that aims to catch cancers before symptoms appear.Shares of the Menlo Park, Calif., company were up 34% this week through Tuesday's close after FDA briefing documents for the meeting, released on Monday, were more favorable than investors had expected.RBC Capital Markets analyst Dan Leonard said the briefing documents suggest the FDA is less concerned with Galleri's safety and effectiveness and more focused on how to label the commercial product.The FDA often turns to advisory committees to obtain advice from experts who work outside of the government when a scientific, technical or policy question arises, such as whether an unapproved product is safe and effective. The agency usually follows the advice of its advisory committees but it isn't bound ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4588","BK4139","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669005631","title":"NASDAQ Trade Halt Halt News Pending at 06:55 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2669005631","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669005631?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:55","pubTimestamp":1790160900,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 06:55 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nAQN2MKEO5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669318122","title":"With Approval Looking Likely, How Fast Will Sales of Cancer-Screening Blood Tests Rise?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669318122","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669318122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 04:10","pubTimestamp":1790107800,"startTime":"0","endTime":"0","summary":"This week's 35% jump in the stock of Grail pretty much prices in a positive vote Wednesday, when outside experts meet with the Food and Drug Administration to advise it on approving the first blood test for many kinds of cancer.With Grail now valued at $4.3 billion, or 19 times the consensus estimate for next year's sales, the stock already seems to be assuming the FDA will approve the test sometime early next year.Both those outcomes look likely. The advance questions posted Monday by the FDA for its advisors focus on the claims Grail should make in marketing its Galleri test to Americans over 50. The agency didn't question the test's safety and accuracy.Labs are permitted to sell tests they develop themselves. Grail is already selling Galleri, but the test is rarely covered by insurance. Last year, Grail had sales of about $150 million.Now the question for investors becomes what kind of sales boost will an approval deliver to Galleri?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU2324357040.USD","SG9999004303.SGD","LU1983299246.USD","SGXZ23171101.USD","LU0432979614.USD","TMED","LU1670628061.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","LU0114720955.EUR","LU2211815571.USD","IE0002141913.USD","GRAL","IE00B2B36J28.USD","SGXZ41872573.SGD","LU0211331839.USD","SG9999002232.USD","PJP","IHI","LU2468319806.SGD","LU2237957811.SGD","LU1691799644.USD","IE00B4R5TH58.HKD","LU0882574055.USD","SG9999002224.SGD","BK4566","LU1914381329.SGD","BK4585","LU1057294990.SGD","IE00BJT1NW94.SGD","ABT","LU0122379950.USD","LU1061106388.HKD","LU2089984988.USD","BK4568","LU0266013472.USD","LU2133065610.SGD","LU1989763427.SGD","BK4504","LU1670627923.USD","LU1989763690.USD","LU1721429402.USD","LU2112291526.USD","BK4592","LU2237957902.USD","BK4139","LU1023059063.AUD","LU0208291251.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669512503","title":"Grail Gains From More Focused FDA Review Before Galleri Advisory Panel, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669512503","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669512503?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:26","pubTimestamp":1790094370,"startTime":"0","endTime":"0","summary":"Grail  faces an \"incrementally positive\" shift toward a narrower and more focused Food and Drug Administration debate ahead of Wednesday's advisory committee meeting on Galleri, its multicancer early detection test, UBS Securities said in a report.The FDA briefing documents show the agency has no major outstanding questions about Galleri's analytical performance, bridging analyses or primary safety results, UBS said Monday in the report. Instead, the panel discussion is expected to center on how the test should be positioned and labeled.A key issue is whether Galleri's stage-specific performance supports an \"early detection\" claim and how broadly any clinical benefit should be reflected in the final indication, the report said. UBS said it still expects FDA approval.UBS reiterated its buy rating on Grail stock with a $105 price target.Price: 108.40, Change: +0.43, Percent Change: +0.40","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GRAL","LABU","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669397143","title":"Canaccord Genuity Remains a Buy on GRAIL Inc (GRAL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669397143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669397143?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:55","pubTimestamp":1790070949,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Kyle Mikson CFA reiterated a Buy rating on GRAIL Inc yesterday and set a price target of $80.00. The company’s shares clo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-grail-inc-gral-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-grail-inc-gral-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRAL","CFA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669556196","title":"Under the Radar: Grail Shares Surge on FDA Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2669556196","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669556196?lang=en_us&edition=fundamental","pubTime":"2026-09-22 06:57","pubTimestamp":1790031420,"startTime":"0","endTime":"0","summary":"Shares of Grail surged 34% Monday after the Food and Drug Administration released documents ahead of an advisory committee meeting Wednesday that will help determine whether the FDA approves the company's multi-cancer blood test.Galleri looks for chemical tags on DNA that tumors shed into the blood. The test flags a cancer signal and predicts the organ where the cancer is present. Grail has sold it by prescription since 2021, but the FDA has never approved a test that screens for multiple cancers.In a U.S. study of more than 25,000 adults, Galleri wrongly flagged cancer in 0.15% of healthy people. The test missed most cancers. It caught roughly one-third of those diagnosed within a year, in that study and in a U.K. trial of about 142,000 people. In the U.K. trial, it caught 14% of Stage 1 cancers, the earliest stage. The FDA has asked advisers whether those numbers justify calling Galleri an \"early detection\" test.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","GRAL","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669164925","title":"Grail Shares Jump 34.6% as US FDA Flags no Major Concerns for Co's Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2669164925","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669164925?lang=en_us&edition=fundamental","pubTime":"2026-09-21 23:40","pubTimestamp":1790005244,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45D0MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669645164","title":"Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review from FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2669645164","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669645164?lang=en_us&edition=fundamental","pubTime":"2026-09-21 23:28","pubTimestamp":1790004480,"startTime":"0","endTime":"0","summary":"Shares of Grail soared ahead of the diagnostic company's meeting with the Food and Drug Administration this week to evaluate premarket approval for its landmark blood test designed to spot multiple ty","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LABU","GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669164979","title":"Grail rallies after FDA releases briefing documents for Galleri test review","url":"https://stock-news.laohu8.com/highlight/detail?id=2669164979","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669164979?lang=en_us&edition=fundamental","pubTime":"2026-09-21 23:20","pubTimestamp":1790004023,"startTime":"0","endTime":"0","summary":"Shares of Grail (GRAL) are up $24.76, or 31%, to $105.53 after the FDA posted briefing documents ahead of the Molecular and Clinical Genetics Panel...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grail-rallies-after-fda-releases-briefing-documents-for-galleri-test-review-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grail-rallies-after-fda-releases-briefing-documents-for-galleri-test-review-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4139","GRAL","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669057169","title":"Grail rises 23.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669057169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669057169?lang=en_us&edition=fundamental","pubTime":"2026-09-21 22:06","pubTimestamp":1789999581,"startTime":"0","endTime":"0","summary":"Grail (GRAL) is up 23.2%, or $18.73 to $99.50. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grail-rises-23-2-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grail-rises-23-2-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668275329","title":"GRAIL Risk-Reward Attractive Ahead of FDA Advisory Committee, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2668275329","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668275329?lang=en_us&edition=fundamental","pubTime":"2026-09-19 00:46","pubTimestamp":1789749962,"startTime":"0","endTime":"0","summary":"GRAIL  has an attractive risk-reward profile ahead of the FDA's Sept. 23 advisory committee meeting on its Galleri multi-cancer detection assay, UBS said in a note.UBS said 225 of 227 public comments submitted to the FDA as of Sept. 15 supported approval, while eight called for stricter labeling, clearer cancer-specific performance disclosures and post-market evidence.The bank expects the FDA briefing documents to provide more clarity on the panel's focus. UBS said the safety profile from the PATHFINDER 2 study provides a strong foundation, while the NHS-Galleri trial's failure to meet its primary endpoint is a notable risk.UBS expects FDA approval next year and said a failure to gain approval could leave the stock trading around $40 to $50 per share, while approval could result in a $150 to $170 per share valuation.UBS reiterated a buy rating and $105 price target.Price: 80.52, Change: +0.57, Percent Change: +0.71","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GRAL","BK4588","LABU","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668995429","title":"Grail's Galleri Test Has Large Market Potential Amid Adoption Curve Concerns, RBC Capital Markets Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2668995429","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668995429?lang=en_us&edition=fundamental","pubTime":"2026-09-17 23:36","pubTimestamp":1789659413,"startTime":"0","endTime":"0","summary":"Grail's  Galleri multi-cancer early detection test could unlock a \"substantial\" market opportunity, but adoption and reimbursement hurdles could limit near-term sales, RBC Capital Markets said in a note Thursday.The investment firm said Galleri could gain US Food and Drug Administration approval in late 2026 or early 2027, which would provide a \"compelling\" catalyst for the stock.Even with potential approval, RBC expects slower sales ramp than Wall Street and sees cash burn increasing year over year in 2027.The firm forecast $430 million in sales in 2030, compared with a consensus estimate of about $512 million, citing \"limited\" demand from patients paying out-of-pocket and a lack of broad insurance coverage.RBC Capital Markets initiated coverage of Grail with a sector perform rating and a price target of $84.Grail's shares were 4.3% higher in Thursday trading.Price: 78.32, Change: +3.21, Percent Change: +4.27","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU0029864427.USD","GSIB","LU1267930573.SGD","LU0128525929.USD","GRAL","BK4207","LU0708994859.HKD","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668966859","title":"RBC Initiates GRAIL at Sector Perform With $84 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2668966859","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668966859?lang=en_us&edition=fundamental","pubTime":"2026-09-17 18:22","pubTimestamp":1789640532,"startTime":"0","endTime":"0","summary":"GRAIL (GRAL) has an average rating of overweight and mean price target of $77.70, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668682089","title":"Grail initiated with a Sector Perform at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2668682089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668682089?lang=en_us&edition=fundamental","pubTime":"2026-09-17 17:10","pubTimestamp":1789636209,"startTime":"0","endTime":"0","summary":"RBC Capital initiated coverage of Grail (GRAL) with a Sector Perform rating and $84 price target The market opportunity for multi-cancer early dete...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grail-initiated-with-a-sector-perform-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grail-initiated-with-a-sector-perform-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","LU1267930573.SGD","GRAL","LU0029864427.USD","GSIB","LU0128525929.USD","BK4139","LU0310800379.SGD","LU0708994859.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667655001","title":"UBS Initiates a Buy Rating on GRAIL Inc (GRAL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667655001","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667655001?lang=en_us&edition=fundamental","pubTime":"2026-09-14 15:35","pubTimestamp":1789371325,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from UBS initiated coverage with a Buy rating on GRAIL Inc and a price target of $105.00. The word on The Street in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-initiates-a-buy-rating-on-grail-inc-gral-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-initiates-a-buy-rating-on-grail-inc-gral-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666535016","title":"Grail Initiated at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2666535016","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666535016?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:30","pubTimestamp":1788960600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GRAL/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538079","title":"UBS Initiates Coverage on GRAIL With Buy Rating, $105 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538079","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538079?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:22","pubTimestamp":1788956579,"startTime":"0","endTime":"0","summary":"GRAIL Inc (GRAL) has an average rating of overweight and mean price target of $66, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664809464","title":"Grail Grants 55,867 Inducement RSUs to 59 New Hires Under NASDAQ Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664809464","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664809464?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:02","pubTimestamp":1788465736,"startTime":"0","endTime":"0","summary":"Grail grants 55,867 inducement RSUs to 59 new hires under Nasdaq rule 5635(c)(4)Grail granted restricted stock units covering 55,867 common shares to 59 recently hired non-executive employees.Awards w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL5Gj8P3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":121,"code":"91000000","status":"200"}]}}